Scarica l'app Stockscreener
7.40
6.32%
0.44
Dopo l'orario di chiusura:
7.47
0.07
+0.95%
Precedente Chiudi:
$6.96
Aprire:
$7.09
Volume 24 ore:
1.43M
Relative Volume:
1.23
Capitalizzazione di mercato:
$498.32M
Reddito:
$141.31M
Utile/perdita netta:
$-297.87M
Rapporto P/E:
-1.3721
EPS:
-5.3933
Flusso di cassa netto:
$-168.20M
1 W Prestazione:
+8.98%
1M Prestazione:
-6.21%
6M Prestazione:
-19.74%
1 anno Prestazione:
-37.07%
Intervallo 1D:
$6.82
$7.42
Intervallo di 1 settimana:
$6.47
$7.7485
Portata 52W:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
7.40 | 468.69M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpHere's Why - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Upgraded to Hold at Zacks Research - MarketBeat
Ginkgo Bioworks (NYSE: DNA) insider plans 2,200-share sale - Stock Titan
How Ginkgo Bioworks Holdings Inc. Class A (DNA) Affects Rotational Strategy Timing - Stock Traders Daily
Ginkgo Bioworks (DNA) Slides 6.22% as Shares Approach Key SupportEntry Point Alerts - vinanet.vn
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Moomoo
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Just Slashed This Year's Revenue Estimates By 22% - simplywall.st
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Ginkgo Bioworks Holdings Inc (DNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ginkgo Bioworks (DNA) Sheds 3.33% as Shares Approach Critical $6.9 SupportStock Buy Zone - vinanet.vn
Kolchinsky Warns Ban on Chinese Biotech Deals Would Hand Pipeline to Novartis - finance.biggo.com
Ginkgo Bioworks (DNA) Short Interest & Short Float | Updated Aug 2026 $DNA - MarketBeat
Ginkgo Bioworks Holdings Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Slammed 36% But Getting In Cheap Might Be Difficult Regardless - 富途牛牛
Ginkgo Bioworks (NYSE:DNA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Ginkgo Bioworks Q2 Earnings Call Highlights - MarketBeat
DNA Downgraded by TD Cowen -- Price Target Lowered to $9.00 - GuruFocus
TD Cowen Downgrades Ginkgo Bioworks(DNA.US) to Hold Rating, Cuts Target Price to $9 - Moomoo
TD Cowen cuts Ginkgo Bioworks stock rating on growth uncertainty - Investing.com India
TD Cowen Downgrades Ginkgo Bioworks to Hold From Buy, Adjusts Price Target to $9 From $12 - marketscreener.com
TD Cowen cuts Ginkgo Bioworks stock rating on growth uncertainty By Investing.com - Investing.com Australia
TD Cowen Downgrades Ginkgo Bioworks Holdings Inc (DNA) to Hold - StreetInsider
Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Ginkgo Bioworks Holdings, Inc. 2Q 2026: Revenue ($46.95M), Net income ($46.71M), EPS ($0.75) — 10-Q Summary - TradingView
Biosecurity sale shapes Ginkgo Bioworks (NYSE: DNA) Q2 2026 results - Stock Titan
Ginkgo Bioworks Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:DNA) 2026-08-06 - Seeking Alpha
Ginkgo Bioworks (NYSE:DNA) Trading Down 9.6%Here's What Happened - MarketBeat
BlackRock, Inc. Buys Ginkgo Bioworks Holdings Inc (DNA) -- Shares Look 32% Overvalued on GF Value - GuruFocus
Earnings call transcript: Ginkgo Bioworks Q2 2026 revenue miss weighs on shares - Investing.com Canada
Ginkgo Bioworks : Q2 2026 Results Presentation - marketscreener.com
Ginkgo Bioworks (NYSE:DNA) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Ginkgo Bioworks (DNA) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 FY2026 earnings call transcript - Yahoo Finance
Ginkgo Bioworks reports Q2 2026 revenue $20.2M, GAAP net loss $57.3M, Adjusted EBITDA ($36.3M) - TradingView
Ginkgo Bioworks (NYSE: DNA) posts Q2 loss, wins $47M lab deal - Stock Titan
(DNA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ginkgo Bioworks (DNA) Surges Nearly 10% as Biotech Sentiment StrengthensRetail Volume - vinanet.vn
Ginkgo Bioworks to Review Q2 2026 Performance - The Globe and Mail
Ginkgo Bioworks (DNA.US) will release its earnings report after market close on August 5. - Moomoo
Ginkgo Bioworks (DNA) CEO Jason R. Kelly receives over 300k new RSUs - Stock Titan
Ginkgo Bioworks (NYSE: DNA) plans Q2 2026 results presentation and Q&A - Stock Titan
Ginkgo Bioworks (DNA) to Release Earnings on Thursday - MarketBeat
Ginkgo Bioworks (DNA) Edges Higher: Holding Above Key Support After 1.1% GainFRAMA Signal - Vinanet
Ginkgo Bioworks Holdings Inc (DNA) Balance Sheet - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.445|Chg%:+0.085 - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):